GPT and cholangitis: Furthermore, in the severe cholangitis group, patients treated with MEPM+IVIG had lower ALT [149.50 (IQR: 88.00–210.50) vs. 196.00 (IQR: 158.00–251.00), P=0.016], AST [118.50 (IQR: 81.50–197.50) vs. 169.00 (IQR: 156.00–225.00), P=0.009] and γ-GGT [479.00 (IQR: 352.50–631.50) vs. 654.00 (IQR: 481.00–847.00), P=0.014] than those treated with MEPM (Table 6).